TheranosticTrials.org

Clinical Trial · NCT06520449

68Ga-NTA-476 Imaging in Prostate Cancer

Overview

This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476. It aims to find out where 68Ga-NTA-476 goes in the body once it is injected into a person and whether there are any side effects or issues with tolerating the compound. This will be compared to an existing imaging compound which is currently used in Australia called 18F-DCFPyl. 68Ga-NTA-476 has been developed and tested in the laboratory; however, this is the first time that it will be tested in humans.

Sponsor

Unknown Organization

Phase

Early Phase 1

Contacts

Prof.Rod Hicks, MB BS, MD, FRACP, FICIS (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06520449

Drug / Compound

NTA-476

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Peptides
Chelator: DOTA
Linker: linker

DCFPyL

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Participants must have a life expectancy of \>3 months in the opinion of the Investigator.
  • Participants must have PSA \> 0.1 ng/mL.
  • Participants on other anti-cancer therapy, such as novel anti-androgen therapy, may be allowed on a case-by-case basis at the principal investigator's discretion, with an agreement of a washout period prior to 68Ga-NTA-476 dosing, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
  • Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 68Ga-NTA-476. Participants must agree to not donate sperm during the study and for 14 days after the injection of 68Ga-NTA-476. Acceptable methods of contraception are described in section 14.3.1 of the Protocol.
  • Participants on chemotherapy may be approved on a case-by-case basis at the principal investigator's discretion if the last dose of chemotherapy is administered at least 3 weeks prior to receipt of 68Ga-NTA-476, and subsequent dose of chemotherapy are to resume following completion of End of Treatment Visit (EOTV), if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
  • Participants with a documented history of histologically confirmed diagnosis of prostate cancer.
  • Eastern Cooperative Oncology Group (ECOG) performance status = 2.

Exclusion

  • Major surgery within 28 days prior to the dose of 68Ga-NTA-476. Exceptions may be approved on a case-by-case basis at the principal investigator's discretion, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 x ULN, or \> 5 x ULN for patients with known liver metastases
  • Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \< 60 mL/min or serum creatinine \>1.5 x upper limit of normal (ULN)
  • Inadequate organ functions as reflected in laboratory parameters:
  • Absolute neutrophil count (ANC) \< 1.0 x 109/L
  • Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.
  • History of uncontrolled allergic reactions and/or known or expected hypersensitivity to peptide therapeutics, including 68Ga-NTA-476 or any of its excipients.
  • Total bilirubin \> 1.5 x ULN, except for patients with documented Gilbert's syndrome who are eligible if total bilirubin = 3 x ULN
  • For participants not taking warfarin or other anticoagulants: international normalised ratio (INR) =1.5 or prothrombin time (PT) =1.5 x ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) =1.5 x ULN. Participants taking warfarin must be on a stable dose that results in a stable INR \<3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
  • Haemoglobin \< 9 g/dL
  • Have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to participants with severe claustrophobia.
  • Residual toxicity \> Grade 1 from prior/current anti-cancer therapy (except alopecia). Participants with \> Grade 1 toxicity from prior anti-cancer therapy may be approved on a case-by-case basis at the principal investigator's discretion, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
  • Platelet count of \< 75 x 109/L